Newsroom

Industry News

27 Jan

InspireMD Receives CE Mark Approval for Its New CGuard RX and Announces Positive Six Month Follow-Up CARENET Trial Data at LINC 2015

The New CGuard™ RX Rapid Exchange System Receives CE Mark Approval Six-Month Ultrasound Analysis Confirms Widely Patent Internal and External Carotid Arteries When Compared to Conventional Carotid Stents. InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it received...

Read more

23 Jan

GeoVax Provides Progress Report on its Ebola Vaccine Program

Ebola Vaccine Demonstrates Production of Virus-Like Particles in Human Cells ATLANTA, GA, January 12, 2015 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its unique vaccine delivery platform, today provided an update on its Ebola virus vaccine development program.   In October 2014,...

Read more

21 Jan

Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET

Presentation to Discuss Capricor’s Duchenne Muscular Dystrophy Clinical Program LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular...

Read more

20 Jan

Prima BioMed Receives $777K R&D Tax Incentive Refund

Prima BioMed Ltd (NASDAQ: PBMD) (ASX:PRR) (“Prima”) is pleased to advise that it has received approximately $777k in a cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided essentially in respect of expenditures incurred on eligible Australian R&D activities conducted on the...

Read more

20 Jan

United Health Products Reports Highly Significant Test Results for HemoStyp(R)

United Health Products Inc. (OTCQB: UEEC) announced that it has received formal results of recent tests performed at Spring Valley Laboratories, a GLP compliant CRO laboratory. These tests were performed on pigs that had their femoral arteries exposed. A 5 millimeter puncture wound was established and the arterial tissue...

Read more

20 Jan

Celator® Pharmaceuticals Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia

Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary...

Read more

20 Jan

Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015

Manufacturing and Quality Control of Clinical and Commercial Quantities of Company’s Lead Drug to Be Discussed With Regulatory Authorities- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a...

Read more

Page 1 of 4112345...102030...Last »

Latest Tweets